Bayer halts asundexian trial, considers restructuring By Investing.com – Investing.com Australia
Reuters. LEVERKUSEN – Bayer AG (ETR:) has ceased its phase III asundexian trial early based on the recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC concluded that asundexian was less effective than apixaban, a current standard treatment, in preventing strokes in patients with atrial fibrillation at risk of stroke. This decision was announced…